

**Amendments to the Claims:**

This listing of claims will replace all previous versions and listings of claims in the application:

1. (currently amended) A method of ~~treating for the therapeutic treatment of~~ psoriasis in a ~~mammal-human~~, comprising administering to the ~~mammal-human~~ a therapeutically effective amount of an antibody which binds ErbB2.
2. (previously presented) The method of claim 1 wherein the antibody blocks ligand activation of an ErbB receptor.
3. (previously presented) The method of claim 2 wherein the antibody blocks binding of monoclonal antibody 2C4 to ErbB2.
- 4.-7. (canceled)
8. (currently amended) The method of claim 1 wherein the antibody ~~has a biological characteristic of binds the same epitope in the extracellular domain of ErbB2 as that bound by~~ monoclonal antibody 2C4.
9. (previously presented) The method of claim 8 wherein the antibody comprises monoclonal antibody 2C4 or humanized 2C4.
10. (previously presented) The method of claim 1 wherein the antibody is an antibody fragment.
11. (previously presented) The method of claim 11 wherein the antibody fragment is a Fab fragment.
12. (previously presented) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.
13. (previously presented) The method of claim 10 wherein the antibody fragment is not conjugated with a cytotoxic agent.

14. (previously presented) The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.

15. (currently amended) The method of claim 17-1 further comprising administering to the human a therapeutically effective amount of a second therapeutic agent selected from the group consisting of another ErbB-~~antagonist antibody~~, an immunosuppressive agent, chemotherapeutic agent, cytotoxic agent, growth inhibitory agent, EGFR-targeted drug, tyrosine kinase inhibitor, anti-angiogenic agent, anti-hormonal compound, cardioprotectant, and cytokine.

16. (currently amended) The method of claim 17-1 comprising administering at least one dose of the antibody to the human in an amount from about 0.5mg/kg to about 30mg/kg.

17.-31. (canceled)

32. (currently amended) The method of claim 17-1 further comprising treating the human with a therapeutically effective amount of a second drug selected from the group consisting of immunosuppressive agent, cyclosporine, tacrolimus (FK506), DAB389 IL2, chemotherapeutic agent, methotrexate, psoralen, steroid, glucocorticosteroid, prednisone, methylprednisolone, OKT-3 monoclonal antibody, azathioprine, bromocryptine, heterologous anti-lymphocyte globulin, anti-LFA-1 antibody, efalizumab, antibody that binds to B-cell surface antigen, anti-CD20 antibody, Rituximab, TNF antagonist, Ethanercept, Infliximab, D2E7, CDP-870, IL-1 antagonist, Kineret, IL-10 agonist, COX-2 inhibitor, another ErbB antagonist, EGFR-targeted drug, tyrosine kinase inhibitor, methoxsalen, hydrocortisone, calcipotriene, anthralin, coal tar, betamethasone, betamethasone acetate/betamethasone sodium phosphate, cortisone acetate, dexamethasone, dexamethasone sodium phosphate, methylprednisolone acetate, hydrocortisone sodium phosphate, prednisolone, and prednisolone sodium phosphate and/or subjecting the patient to phototherapy.

33.-46. (canceled)